Rep. Tim Moore Purchases Shares of Genprex (NASDAQ:GNPX)

Representative Tim Moore (R-North Carolina) recently bought shares of Genprex (NASDAQ:GNPX). In a filing disclosed on January 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Genprex stock on December 18th.

Representative Tim Moore also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Cracker Barrel Old Country Store (NASDAQ:CBRL) on 12/31/2025.
• Purchased $15,001 – $50,000 in shares of Harley-Davidson (NYSE:HOG) on 12/18/2025.
• Purchased $15,001 – $50,000 in shares of Cracker Barrel Old Country Store (NASDAQ:CBRL) on 12/16/2025.
• Purchased $15,001 – $50,000 in shares of Verizon Communications (NYSE:VZ) on 12/10/2025.
• Sold $50,001 – $100,000 in shares of Cracker Barrel Old Country Store (NASDAQ:CBRL) on 12/10/2025.
• Purchased $50,001 – $100,000 in shares of Cracker Barrel Old Country Store (NASDAQ:CBRL) on 12/9/2025.
• Purchased $15,001 – $50,000 in shares of Harley-Davidson (NYSE:HOG) on 12/9/2025.
• Sold $100,001 – $250,000 in shares of Hyster-Yale (NYSE:HY) on 12/3/2025.
• Sold $15,001 – $50,000 in shares of Cracker Barrel Old Country Store (NASDAQ:CBRL) on 11/28/2025.
• Sold $15,001 – $50,000 in shares of Harley-Davidson (NYSE:HOG) on 11/28/2025.

Genprex Stock Up 5.8%

GNPX stock opened at $2.00 on Friday. The firm has a 50 day moving average of $3.04 and a two-hundred day moving average of $8.67. Genprex has a 12 month low of $1.71 and a 12 month high of $55.00. The company has a market capitalization of $4.64 million, a price-to-earnings ratio of -0.08 and a beta of -0.81.

Genprex (NASDAQ:GNPX) last released its quarterly earnings data on Friday, November 14th. The company reported ($5.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($12.50) by $7.50. On average, research analysts expect that Genprex will post -5.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Genprex

An institutional investor recently raised its position in Genprex stock. Susquehanna International Group LLP boosted its holdings in shares of Genprex (NASDAQ:GNPX) by 11.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 340,056 shares of the company’s stock after purchasing an additional 35,661 shares during the period. Susquehanna International Group LLP owned about 27.20% of Genprex worth $58,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 14.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Wall Street Zen raised Genprex to a “sell” rating in a research report on Saturday, October 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

About Representative Moore

Timothy K. Moore (Republican Party) is a member of the U.S. House, representing North Carolina’s 14th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Moore (Republican Party) ran for election to the U.S. House to represent North Carolina’s 14th Congressional District. He won in the general election on November 5, 2024.

Moore served as speaker of the House from 2015 to 2025.

Timothy Moore earned his B.A. from the University of North Carolina-Chapel Hill in 1992 and his J.D. from the Oklahoma City University School of Law in 1995. His professional experience includes working as an attorney.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.